1. Introduction {#sec1}
===============

Pregnant women and neonates are at greater risk for influenza-related complications than the general population \[[@B1], [@B2]\]. Most institutions and organizations recommend that all pregnant women receive the trivalent inactivated influenza virus vaccine \[[@B3]--[@B8]\]. Such endorsements rely on the immunogenic response of the mothers, the lack of teratogenicity, and the contrandication of immunization in children younger than six months \[[@B7], [@B9]--[@B11]\].

Despite the broad recommendation to vaccinate pregnant women against influenza, coverage is still limited. A survey held by the Centers for Disease Control and Prevention involving women who were pregnant from October 2011 to January 2012 showed that only half of the respondents had been vaccinated and fewer than 10% had received the vaccine before giving birth \[[@B12]\]. Similar patterns were found in previous studies \[[@B13]\].

Although there is clear evidence of the efficacy of the influenza vaccine for the general population \[[@B14]\], to our knowledge, a systematic approach with regard to the evidence of the therapeutic effects of influenza vaccination in pregnant women is lacking. Our objective is to review the effects of influenza vaccination in preventing influenza-related outcomes in pregnant women and their infants.

2. Methods {#sec2}
==========

2.1. Eligibility Criteria for the Included Studies {#sec2.1}
--------------------------------------------------

We selected randomized controlled trials or cohort studies that assessed the effects of inactivated influenza vaccine in preventing influenza-related outcomes in pregnant women and their offspring compared with placebo, other vaccines, or no vaccines. We excluded studies that assessed monovalent vaccines, such as the H1N1 influenza vaccine, because they are used for specific epidemic situations.

2.2. Data Sources and Search Strategy {#sec2.2}
-------------------------------------

We searched for eligible studies in the following databases (from inception to September 2013): MEDLINE, Embase, Scopus, Centre for Reviews and Dissemination (CRD), Cochrane Central Register of Controlled Trials (CENTRAL), metaRegister of Current Controlled Trials (mCRT), Latin American and Caribbean Center on Health Sciences Information (LILACS), and Scientific Electronic Library Online (SciELO). References to relevant publications in the field were also screened to identify potentially eligible studies. There were no restrictions on language, length of followup, publication date, or publication status. Those databases comprise the main sources of cohort studies and clinical trials.

We used the following search terms to search MEDLINE (via PubMed) and adapted the strategy for the other databases: ("influenza, human"\[mesh\] or "influenza"\[tiab\] or "human flu"\[tiab\] or "influenza"\[tiab\] or "influenzas"\[tiab\] or "grippe"\[tiab\] or "flu"\[tiab\] or "cold"\[tiab\]) and ("influenza vaccines"\[mesh\] or "influenza vaccines"\[tiab\] or "vaccine"\[tiab\] or "vaccine"\[tiab\] or "vaccines"\[tiab\]) and ("mothers"\[mesh\] or "mothers"\[tiab\] or "pregnancy"\[mesh\] or "pregnancy"\[tiab\] or "gestation"\[tiab\] or "pregnant women"\[mesh\] or "pregnant women"\[tiab\] or "pregnant"\[tiab\]) and ("infant"\[mesh\] or "infant"\[tiab\] or "infants"\[tiab\] or "infant, newborn"\[mesh\] or "newborn"\[tiab\] or "newborns"\[tiab\] or "fetus"\[mesh\] or "fetus"\[tiab\] or "foetus"\[tiab\] or "fetal"\[tiab\] or pregnancy).

2.3. Study Selection and Data Collection Process {#sec2.3}
------------------------------------------------

Two independent reviewers (EB and LABL) selected the studies by assessing titles and abstracts and extracted the data. Disagreements were resolved by consensus or a third reviewer (TFG). The extracted data consisted of the following: year, country, study design, gestational age, type of vaccine, posology, comparators, sample size, followup, and outcomes. When necessary, we contacted the corresponding authors for additional information.

2.4. Risk of Bias and Quality Assessment {#sec2.4}
----------------------------------------

To assess the risk of bias of randomized controlled trials (RCT), we used the Cochrane Collaboration tool \[[@B15]\], which includes judgments about the sequence generation, allocation sequence concealment, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias. For observational studies, we evaluated the following: eligibility criteria, measurements of exposures and outcomes, control of confounding, and followup \[[@B16]\].

We assessed the quality of evidence for each relevant outcome with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) \[[@B17], [@B18]\]. For this evaluation, we separated the bodies of evidence into "experimental" and "observational" centered on RCT and cohort studies, respectively. Following the GRADE approach, RCT started the evaluation with "high quality" and cohort studies with low quality of evidence. Then, we assessed the evidence against five items that could decrease its quality: limitations (risk of bias), inconsistency, indirectness, imprecision, and publication bias. After assessing these items, the resulting quality of evidence could be rated as high, moderate, low, or very low. When distinct levels of quality were available for the same outcome, we considered the experimental design (RCT) evidence in rating the quality.

The final judgments regarding the risk of bias and evidence quality were achieved by consensus. We considered the quality assessment results when interpreting the findings.

2.5. Data Analysis {#sec2.5}
------------------

The primary outcome was the incidence of influenza-like illness, which was defined as fever and either cough or sore throat. For infants\' outcomes, we defined small for gestational age as a weight below the 10th percentile and prematurity as birth before a gestational age of 37 complete weeks.

We extracted the estimates along with 95% confidence intervals (95% CI) according to the data available in the original studies (relative risk (RR), odds ratio (OR), or hazard ratio (HR)). If reported, we only considered the adjusted estimates and did not perform further calculation. We attempted to perform meta-analyses using random effects models, if numerical data from studies allowed a summarization.

3. Results {#sec3}
==========

Our search retrieved 1,967 records. Twenty-three records were selected for full-text assessment, and nine were included in the review. The reasons for exclusions are depicted in [Figure 1](#fig1){ref-type="fig"} \[[@B19]--[@B33]\]. were related to eight unique studies that enrolled 182,820 pregnant women and 182,246 neonates \[[@B34]--[@B42]\].

3.1. Study Characteristics {#sec3.1}
--------------------------

[Table 1](#tab1){ref-type="table"} describes the main characteristics of the included studies. Except for one, all studies were published from 1990 to 2012. We identified one RCT conducted in Bangladesh and seven cohort studies performed in the United States.

The trivalent inactivated vaccine was the most common intervention and was assessed in seven studies \[[@B35]--[@B41]\]. One cohort used the polyvalent inactivated vaccine \[[@B34]\]. Newborns were not vaccinated. Only the RCT had an active control group (pneumococcal vaccine) \[[@B38]\]. Nearly the entire sample of pregnant women came from three retrospective cohorts \[[@B35], [@B37], [@B41]\]. The data in the retrospective studies came from medical records. The length of followup of each outcome varied among studies and lasted up to 36 weeks. Some studies adjusted their results for confounding factors, such as the women\'s age, week of delivery, infant\'s gender, and gestational age.

Observational studies that compared baseline characteristics of the groups showed that most variables did not differ between the groups. Some studies showed that vaccinated women had a worse profile than unvaccinated women, which were of higher risk for complications \[[@B37]\], were older, and had higher body mass index, higher parity, and more multiple gestation \[[@B42]\]. One study observed that vaccinated mothers had more health insurance than unvaccinated ones \[[@B41]\]. All studies controlled the identified confounding through multivariable analysis.

3.2. Outcomes and Quality of Evidence {#sec3.2}
-------------------------------------

We could not perform meta-analysis because the studies used different measures of association for the same outcome; the estimates are presented as available in the studies.

[Table 2](#tab2){ref-type="table"} depicts the results of each outcome and the quality assessment. Mothers who received the influenza vaccine had a lower incidence of influenza-like illness, as did their infants (high-quality evidence), but there was no difference found for influenza-like illness with fever higher than 38°C (moderate-quality evidence). A lower incidence of influenza in infants, as confirmed by laboratory tests, was also observed (moderate-quality evidence).

Very-low-quality evidence showed no difference between comparisons with regard to the incidence of upper respiratory infection, hospitalization, and medical visits for influenza-like illness in mothers and infants.

Two studies found no difference in the incidence of hospitalization for influenza-like illness in infants \[[@B35], [@B37]\]; in one study, the reduction in the rate of hospital admission was significant \[[@B40]\]. With regard to medical visits for influenza-like illness in infants, the observational studies showed no significant differences \[[@B35], [@B37], [@B40]\], and the RCT showed a reduction in such rate \[[@B38]\] (moderate-quality evidence).

For the outcomes prematurity and small for gestational age, conflicting results were found across the studies. One single cohort \[[@B42]\] indicated significant reduction in stillbirth and neonatal death among the influenza-vaccinated group (moderate-quality evidence).

We did not assess the incidence of adverse reactions because the included studies did not systematically evaluate this outcome. In general, influenza vaccination had no association with local or minor systemic effects, fever, Apgar score at one minute, hyperbilirubinemia, or major malformations.

4. Discussion {#sec4}
=============

The influenza vaccine was found to reduce the risk of influenza-like illness in mothers and infants as well as the risk of laboratory-confirmed influenza in infants. Such findings are supported by high- and moderate-quality evidence. Other outcomes showed no significant differences between the compared groups. Adverse reactions were not systematically assessed across the studies, but there was no evidence of increase in clinically relevant risk related to influenza vaccination during pregnancy. A big cohort study that focused on the safety of trivalent inactivated influenza vaccine, however, did not find any increased risk of adverse events and adverse obstetric events in the vaccinated mothers, when compared to unvaccinated pregnant women \[[@B43], [@B44]\].

Other factors can prevent influenza in infants such as the effect of breast-feeding \[[@B45]\] and immunization of all the infant\'s close contacts, also known as cocooning \[[@B46]\]. To avoid confounding and enable comparison, groups should be set by randomization. In the present review, however, only one RCT was identified and included. Although most observational studies performed multivariate analyses, residual confounding may remain even after adjustment because this statistical procedure cannot control for all biological variabilities \[[@B47]\].

Controversy may rise about the possible differences between the groups from observational studies. Women receiving influenza vaccine would have more medical attention and be healthier than unvaccinated pregnant women; thus, the result found would be attributed to the health profile of vaccinated women rather than to the vaccine itself. However, some studies reported that vaccinated women were at high risk during gestation, and this difference was also statistically controlled \[[@B37], [@B42]\]. Studies consistently reported that the patients and the clinicians made the decision about taking influenza vaccine or not. Surveys about attitudes and beliefs of these actors regarding influenza vaccination in pregnancy show that the proportion of people who do not believe vaccine is safe is still high \[[@B48], [@B49]\].

Another limitation of our review is the absence of the systematic reporting of adverse reactions. Although the incidence of adverse reaction was not shown to be a concern in the included studies, this lack of evidence may inadvertently lead to the conclusion that this risk is minimal or nonexistent \[[@B50]\]. Individuals with egg allergy, for example, require caution when receiving trivalent inactivated influenza vaccine \[[@B7]\].

Previous narrative reviews concluded that influenza vaccination is safe, that there has been no evidence of teratogenicity, and that many countries recommend influenza vaccination among women with both healthy and high-risk pregnancies \[[@B9], [@B51]--[@B56]\]. The role of education of patients and doctors in increasing adherence to maternal vaccination was also emphasized \[[@B57]--[@B59]\]. One systematic review assessed the benefits and dangers of the influenza vaccine in special populations---pregnant women included---but limited the eligible studies to RCTs only \[[@B60]\]. Another study reviewed the beneficial effects on the influenza vaccine on infants only \[[@B61]\].

Some barriers still persist to the implementation of influenza vaccine during pregnancy. Apprehensions about the use of thimerosal-containing influenza vaccines, based on theoretical risk of harm to the fetal brain, were widely spread in scientific and lay communities during the past years \[[@B55], [@B62]\]. Subsequent research proved that no causal relation existed between immunization with vaccine containing thimerosal preservative---including exposure during pregnancy---and neuropsychological outcomes \[[@B63], [@B64]\]. The most recent report of the Global Advisory Committee on Vaccine Safety of the World Health Organization considered that available evidence strongly supports the safety of the use of thimerosal as a preservative for inactivated vaccines \[[@B65]\]. It is expected that with the availability of higher-quality evidence, such concerns can be demystified.

Attending to claims for more evidence \[[@B66], [@B67]\], several RCTs assessing influenza vaccination in pregnancy are planned and some are ongoing \[[@B68]--[@B77]\]. Such RCTs focus on different populations, such as HIV-positive mothers, and factors that interfere with immunization coverage. We expect that, following the publication of these trials, the availability and quality of the evidence will radically improve. Additionally, the issue about the comparability between the vaccinated and unvaccinated groups will be more properly addressed.

5. Conclusion {#sec5}
=============

Maternal immunization for influenza significantly reduced the incidence of influenza-like illness in women and infants. For clinical practice, the findings reinforce the current recommendations to vaccinate all pregnant women against influenza. We are not confident in making conclusions about other outcomes. Further studies should address this lack of evidence and enhance the overall quality of the outcomes.
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###### 

Main characteristics of the included studies.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                  Period of enrollment   Country      Study design                   Influenza vaccine group (*N*)   Control group (*N*)     Gestational month at immunization
  -------------------------------------- ---------------------- ------------ ------------------------------ ------------------------------- ----------------------- -----------------------------------
  Hulka 1964 \[[@B34]\]                  1962-1963              USA          Prospective cohort             Polyvalent inactivated (363)    Placebo\                \>3rd\*
                                                                                                                                            (181)                   

  Black et al. 2004 \[[@B35]\]           1997--2002             USA          Retrospective cohort           Trivalent inactivated (3,707)   No vaccine (45,878)     7th--9th

  Munoz et al. 2005 \[[@B36]\]           1998--2003             USA          Matched retrospective cohort   Trivalent inactivated (225)     No vaccine\             4th--9th
                                                                                                                                            (826)                   

  France et al. 2006 \[[@B37]\]          1995--2001             USA          Matched retrospective cohort   Trivalent inactivated (3,160)   No vaccine (37,969)     4th--9th

  Zaman et al. 2008 \[[@B38], [@B39]\]   2004-2005              Bangladesh   Randomized controlled trial    Trivalent inactivated (172)     Pneumococcal vaccine\   7th--9th
                                                                                                                                            (168)                   

  Eick et al. 2011 \[[@B40]\]            2002--2005             USA          Prospective cohort             Trivalent inactivated (573)     No vaccine\             4th--9th
                                                                                                                                            (587)                   

  Omer et al. 2011 \[[@B41]\]            2004--2006             USA          Retrospective cohort           Trivalent inactivated (578)     No vaccine (3,590)      1st--9th

  Sheffield et al. 2012 \[[@B42]\]       2003--2008             USA          Retrospective cohort           Trivalent inactivated (8,690)   No vaccine (76,153)     1st--9th^†^
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Data assumed by the authors from information available in the paper.

^†^From October 2003 through March 2004, women were vaccinated in the second and third trimesters. From October 2004 through March 2008, women were vaccinated in all three trimesters.

*N*: number of pregnant women in each group.

USA: United States of America.

###### 

Outcomes and the quality of evidence of influenza vaccination in pregnant women.

  Outcome                                      Population                     Study                                  Followup (weeks)        Measure of association   Result (95% CI)         Quality of evidence
  -------------------------------------------- ------------------------------ -------------------------------------- ----------------------- ------------------------ ----------------------- ---------------------
  Influenza-like illness                       Mothers                        Hulka 1964 \[[@B34]\]                  12 to 30                RR                       0.56 (0.35--0.91)^†^    High
  Zaman et al. 2008 \[[@B38]\]                 24 to 36\*                     IRR                                    0.64 (0.43--0.96)^†^                                                     
  Infants                                      Zaman et al. 2008 \[[@B38]\]   24                                     IRR                     0.71 (0.54--0.93)^†^     High                    
                                                                                                                                                                                              
  Influenza-like illness with fever \>38°C     Mothers                        Zaman et al. 2008 \[[@B38]\]           24 to 36\*              IRR                      0.57 (0.30--1.09)^†^    Moderate^a^
  Infants                                      Zaman et al. 2008 \[[@B38]\]   24                                     IRR                     0.72 (0.49--1.05)^†^     Moderate^a^             
                                                                                                                                                                                              
  Laboratory-confirmed influenza               Infants                        Zaman et al. 2008 \[[@B38]\]           24                      IRR                      0.37 (0.15--0.95)^†^    Moderate^a^
  Eick et al. 2011 \[[@B40]\]                  26                             RR                                     0.59 (0.37--0.93)                                                        
                                                                                                                                                                                              
  Acute upper respiratory tract infection      Mothers                        Munoz et al. 2005 \[[@B36]\]           1.1 to 26               RR                       1.84 (0.87--3.87)^†^    Very low^a,b^
  Infants                                      Munoz et al. 2005 \[[@B36]\]   5 to 26                                RR                      1.13 (0.87--1.44)^†^     Very low^a,b^           
  France et al. 2006 \[[@B37]\]                ≤13                            RR                                     0.83 (0.64--1.08)^†^                                                     
                                                                                                                                                                                              
  Hospitalization for influenza-like illness   Mothers                        Munoz et al. 2005 \[[@B36]\]           6                       RR                       3.67 (0.23--58.47)^†^   Very low^a,b^
  Infants                                      Black et al. 2004 \[[@B35]\]   ≤17                                    HR                      0.63 (0.30--1.29)        Very low^a,b,c^         
  Munoz et al. 2005 \[[@B36]\]                 1.1 to 26                      RR                                     3.73 (0.23--59.39)^†^                                                    
  France et al. 2006 \[[@B37]\]                ≤13                            RR                                     1.39 (0.42--4.58)^†^                                                     
  Eick et al. 2011 \[[@B40]\]                  26                             RR                                     0.61 (0.45--0.84)                                                        
                                                                                                                                                                                              
  Medical visit for influenza-like illness     Mothers                        Black et al. 2004 \[[@B35]\]           16 or less              HR                       1.00 (0.84--1.20)       Moderate^a^
  Munoz et al. 2005 \[[@B36]\]^†^              1.1 to 26                      RR                                     1.35 (1.02--1.78)^†^                                                     
  Zaman et al. 2008 \[[@B38]\]                 24 to 36\*                     IRR                                    0.75 (0.39--1.44)^†^                                                     
  Infants                                      Black et al. 2004 \[[@B35]\]   ≤17                                    HR                      0.96 (0.89--1.03)        Moderate^a^             
  France et al. 2006 \[[@B37]\]                ≤13                            RR                                     0.96 (0.86--1.07)                                                        
  Zaman et al. 2008 \[[@B38]\]                 24                             IRR                                    0.58 (0.41--0.82)^†^                                                     
  Eick et al. 2011 \[[@B40]\]                  26                             RR                                     0.92 (0.73--1.16)                                                        
                                                                                                                                                                                              
  Prematurity                                  Infants                        Black et al. 2004 \[[@B35]\]           At birth                RR                       1.10 (0.97--1.23)^†^    Very low^a,b^
  Munoz et al. 2005 \[[@B36]\]                 At birth                       OR                                     0.67 (0.32--1.32)                                                        
  Zaman et al. 2008 \[[@B38], [@B39]\]         At birth                       OR                                     0.48 (0.08--2.74)       Moderate^a^                                      
  Omer et al. 2011 \[[@B41]\]^‡^               At birth                       OR                                     0.60 (0.38--0.94)                                                        
  Sheffield et al. 2012 \[[@B42]\]^†^          At birth                       OR                                     0.86 (0.78--0.95)                                                        
                                                                                                                                                                                              
  Small for gestational age                    Infants                        Zaman et al. 2008 \[[@B38], [@B39]\]   At birth                OR                       0.44 (0.19--0.99)       Moderate^a^
  Omer et al. 2011\[[@B41]\]^‡^                At birth                       OR                                     0.74 (0.47--1.15)                                                        
  Sheffield et al. 2012 \[[@B42]\]^†^          At birth                       OR                                     1.00 (0.93--1.07)                                                        
                                                                                                                                                                                              
  Stillbirths                                  Infants                        Sheffield et al. 2012 \[[@B42]\]^†^    All months              OR                       0.61 (0.42--0.88)       Moderate^a^
                                                                                                                                                                                              
  Neonatal death                               Infants                        Sheffield et al. 2012 \[[@B42]\]^†^    All months              OR                       0.55 (0.35--0.88)       Moderate^a^

IRR: incidence rate ratio; RR: relative risk; HR: hazard ratio; OR: odds ratio.

Notes: \*women were followed during pregnancy, beginning at two weeks after vaccination until delivery and continuing for 24 weeks after delivery. ^†^Data calculated by the authors from information available in the paper. ^‡^Outcome measured at the peak of the influenza season.

Reasons for rating down the on-the-quality assessment using the GRADE approach.

^a^Serious imprecision: low number of events.

^b^The study design was observational.

^c^Serious inconsistency: results vary greatly across studies.
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